Market Pulse Archives

Dec. 9, 2019, 11:04 a.m. EST

Fate Therapeutics' stock rises on early-stage cancer drug data

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Fate Therapeutics Inc. (FATE)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Fate Therapeutics /zigman2/quotes/209623007/composite FATE +1.45% gained 37% after it shared promising data from one clinical and one preclinical study for its experimental cancer immunotherapy treatments. The company is testing two therapies, FT516 and FT500, in a very small Phase 1 trial as treatments for acute myeloid leukemia and as a combination therapy for advanced B-cell lymphoma. Separately, Fate said preclinical data for FT596 was also positive, and it will begin enrolling patients in its first human trial early next year. Fate's stock is up 46% year-to-date. The S&P /zigman2/quotes/210599714/realtime SPX +0.83% has gained 25% during the same timeframe.

/zigman2/quotes/209623007/composite
US : U.S.: Nasdaq
$ 39.97
+0.57 +1.45%
Volume: 881,845
Sept. 30, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$3.47 billion
Rev. per Employee
$45,577
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,363.00
+27.53 +0.83%
Volume: 2.62B
Sept. 30, 2020 5:20p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.